Skip to main content

Search This Blog

Pulmonary Hypertension

Posts

HFpEF: Heart Failure with Preserved Ejection Fraction

Get link
Facebook
X
Pinterest
Email
Other Apps

October 17, 2026

Invalid Access Key! Invalid Access Key!

Pulmonary Vascular Dysfunctions in Cystic Fibrosis

Get link
Facebook
X
Pinterest
Email
Other Apps

October 17, 2026

Invalid Access Key! Invalid Access Key!

Abstract - 2026 - Pediatric Pulmonology

Get link
Facebook
X
Pinterest
Email
Other Apps

October 17, 2026

Invalid Access Key! Invalid Access Key!

HFpEF: Heart Failure with Preserved Ejection Fraction

Get link
Facebook
X
Pinterest
Email
Other Apps

October 13, 2026

Invalid Access Key! Invalid Access Key!

Group 3 Pulmonary Hypertension: From Bench to Bedside

Get link
Facebook
X
Pinterest
Email
Other Apps

October 13, 2026

Invalid Access Key! Invalid Access Key!

Abstract - 2026 - Pediatric Pulmonology

Get link
Facebook
X
Pinterest
Email
Other Apps

October 13, 2026

Invalid Access Key! Invalid Access Key!

A Review of the Mechanism of Action of Drugs Used in Congestive Heart Failure in Pediatrics

Get link
Facebook
X
Pinterest
Email
Other Apps

October 12, 2026

Invalid Access Key! Invalid Access Key!

Powered by Blogger

Theme images by 4x6

Archive

October17
September59
August59
July47
June22
May41
April32
March70
February59
January81

Show more Show less

Popular posts from this blog

Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News

Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News Posted: 02 Mar 2020 12:00 AM PST Aria CV announced the end of a funding round that will be used to finance a feasibility study of its medical device, the Pulmonary Hypertension System (Aria CV PH System), in people with pulmonary arterial hypertension (PAH) in the U.S. The series B round, which raised $31 million, was led by Xeraya Capital . "Aria CV is now well positioned to drive our clinical research forward," Dan Gladney, the company's chief executive officer and president, said in a press release . "We are grateful for this validation by our investors and remain committed to bringing this innovative treatment option to PAH patients," Gladney added. Pulmonary hyperte...

Afib: Causes, Symptoms, and Treatment Options

medical pah :: Article Creator As PAH Science Advances, Trial Design Comes Under Microscope Investigators are considering how best to interpret the results of potential new therapies. The science of pulmonary arterial hypertension (PAH) has advanced significantly in recent years. However, as the push for new and better therapies gains momentum, clinical trial investigators are thinking long and hard about how best to demonstrate and interpret patient improvement. One issue has to do with the question of which end points are best to meaningfully track patient responses to therapies. Marius Hoeper, MD, of Germany's Hannover Medical School, said in clinical practice, physicians tend to use a variety of measures to track patient improvement. "PH physicians usually take a holistic view," he said, "i.E., they consider the broad picture." That broad picture includes everything from patient's exercise capacity, assessed b...

Health Care in Your Future Summit – BizWest Events - BizWest

January 29, 2023

The 11th annual Health Summit will showcase over 16 speakers and panelists about important topics for the Northern Colorado healthcare, business, and citizen communities Join us on Wednesday, November 30, 2022 for the Health Care in Your Future Summit. Session Topics include: • Healthcare Innovations • The Future of Healthcare Workforce / Building the Pipeline • Are we there yet?? COVID Workforce and crisis management adjustments • Supporting Employee Behavioral Health • "The doctor will see you now" • Colorado Healthcare Legislative Update and Preview More than 200 people are expected at this year's summit. A virtual/ hybrid ticket is available for purchase for day of participation. In-person attendance ticket will be required for admittance to the event at The Ranch. Cost to attend In-Person: $32 Cost to attend In-Person + Scholarship Contribution: $45 Cost for virtual/hybrid ticket: $20 Scholarship registrations are available by request to nocohealthsector@gmail.co...

Labels

"pulmonary hypertension prognosis" - Google News
idiopathic pulmonary hypertension
IFTTT
mild pulmonary hypertension
pulmonary artery hypertension
Pulmonary Hypertension
pulmonary hypertension causes
pulmonary hypertension diagnosis
pulmonary hypertension medications
pulmonary hypertension prognosis

pulmonary hypertension symptoms
pulmonary hypertension treatment
severe pulmonary hypertension
what is pulmonary hypertension

Show more Show less

yand